The promise and peril of GLP-1 agonists: What we do (and don’t) know as of August 2024
Discover the latest on GLP-1 agonists: from their unprecedented weight-loss effects to potential risks, and more as of August 2024.
At a glance
Read on to get our full commentary, or use the links below to jump to a specific area of interest:
Across the past two years, GLP-1 agonists—a class of drugs that treat type 2 diabetes (T2D) and obesity—have not only become a major source of industry discourse, but a household name. These medications, which mimic the functions of the naturally occurring hormone GLP-1 (glucagon-like peptide-1), have been lauded for their efficacy in not only controlling blood sugar levels but also promoting weight loss.
As of mid-2024, a full 6% of US adults are actively taking GLP-1 agonists, but the huge potential addressable market for these drugs, combined with an ongoing shortage, means that these medications have plenty of additional potential running room. These levels of demand—and the pervasiveness of these drugs in the public domain—are virtually unprecedented, meaning that all healthcare professionals and industry generalists must stay on top of developments in this space.
In today’s post, we’ll break down what we do—and don’t—know about these medications as of August 2024.
Union Healthcare Insight
Log in to continue reading
Not a member yet? Create a free account for limited access.
Related insights
Can AI help close a persistent gap in cardiovascular care?
What’s next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care
Specialty value-based care: The next phase of VBC